Skip to main content

Table 1 Efficacy outcomes with antiangiogenic agents in recurrent glioblastoma.

From: Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: Analysis of single-agent and combined modality approaches

Reference, (na) Treatment regimen Response rate (%)b Progression-free survival
   CR PR SD Median At 6 months (%)
Bevacizumab       
Vredenburgh [28], (n = 23 of 32)d BV + irinotecan 4 57 35 20 weeks 30
Vredenburgh [29], (N = 35) BV + irinotecan 57 N/A 24 weeks 46
Narayana [33], (n = 37 of 61)e BV + irinotecan or carboplatin 13 60 21 5 months N/A
Friedman [31], Cloughesy [32], (N = 167) BV alone (n = 85)
BV + irinotecan (n = 82)
28
38
N/A
N/A
4.2 months
5.6 months
43
50
Reardon [38], (n = 27 of 59)d BV + etoposide 4 19 70 18 weeks 44
Kreisl [49], (N = 48) BV → BV + irinotecan 71 (Levin criteria); 35 (MacDonald criteria) N/A 16 weeks 29
Gutin [92], (n = 20 of 25)d BV + hypofractionated stereotactic irradiation 50 N/A 7.3 months 65
Aflibercept       
De Groot [53], (n = 32 of 48)d Aflibercept alone 0 30 52 N/A N/A
Cediranib       
Batchelor [112], (N = 31) Cediranib alone 57 (volumetric criteria); 27 (MacDonald criteria) N/A 117 days 26
Cilengitide       
Reardon [50] (N = 81) Cilengitide alone (2000 mg/d [n = 40] or 500 mg/d [n = 41]) 0 9 N/A 2000 mg/d, 8.1 weeksc
500 mg/d, 7.9 weeksc
2000 mg/d, 15
500 mg/d, 10
CT-322       
Schiff [113], (n = 51) CT-322 alone (n = 33)
CT-322 + irinotecan (n = 18)
1 (3)
0
1 (3)
0
N/A
N/A
N/A
N/A
23
48
XL184       
Wen [54], (n = 105) XL184 175 mg qd
XL 184 125 mg qd
AAT-naive (n = 34), 21
AAT-pretreated (n = 12), 8
AAT-naive (n = 37), 30
AAT-pretreated (n = 22), 0
N/A AAT-naive, 16 weeks
AAT-naive, 16 weeks
AAT-pretreated, 7.9 weeks
AAT-naive, 10
AAT-naive, 25
AAT-pretreated, 0
  1. Abbreviations: AAT = antiangiogenic therapy; BV = bevacizumab; CR = complete response; N/A = not available; PR = partial response; RT = radiotherapy; SD = stable disease.
  2. aNumber of patients with glioblastoma, where available.
  3. bIn evaluable patients.
  4. cTime to progression.
  5. dEfficacy outcomes are reported for patients with glioblastoma only.
  6. eEfficacy outcomes are reported for all patients.